Nuvectra Corp (NVTR) Receives $23.67 Average Price Target from Analysts
Nuvectra Corp (NASDAQ:NVTR) has been assigned an average rating of “Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $23.67.
NVTR has been the topic of several recent research reports. Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 target price on shares of Nuvectra in a report on Wednesday, August 8th. JMP Securities increased their target price on shares of Nuvectra from $18.00 to $23.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 8th. Zacks Investment Research cut shares of Nuvectra from a “buy” rating to a “hold” rating in a report on Wednesday, August 29th. Finally, BidaskClub upgraded shares of Nuvectra from a “hold” rating to a “buy” rating in a report on Saturday, November 3rd.
Nuvectra stock traded down $0.76 during midday trading on Monday, hitting $18.38. 133,023 shares of the company’s stock were exchanged, compared to its average volume of 200,260. The company has a debt-to-equity ratio of 0.42, a current ratio of 7.63 and a quick ratio of 7.35. Nuvectra has a 12 month low of $7.60 and a 12 month high of $25.17. The stock has a market cap of $336.33 million, a price-to-earnings ratio of -4.36 and a beta of -0.34.
In other Nuvectra news, President Joseph Paul Hanchin sold 1,250 shares of the stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $20.43, for a total transaction of $25,537.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in NVTR. BlackRock Inc. lifted its position in shares of Nuvectra by 422.6% during the second quarter. BlackRock Inc. now owns 825,252 shares of the company’s stock valued at $16,943,000 after buying an additional 667,346 shares during the last quarter. Peregrine Capital Management LLC purchased a new stake in shares of Nuvectra during the third quarter valued at about $13,140,000. Russell Investments Group Ltd. lifted its position in shares of Nuvectra by 100.5% during the third quarter. Russell Investments Group Ltd. now owns 540,772 shares of the company’s stock valued at $11,888,000 after buying an additional 271,081 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Nuvectra during the third quarter valued at about $5,495,000. Finally, EAM Investors LLC purchased a new stake in shares of Nuvectra during the second quarter valued at about $5,036,000. 81.18% of the stock is owned by institutional investors and hedge funds.
Nuvectra Company Profile
Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.
Featured Article: How to Invest in an Index Fund
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.